利波卡林传奇:洞察其在癌症相关缓解症中的作用
1National Forensic Sciences University, Gandhinagar 382007, Gujarat, India.
Biochimica et biophysica acta. Molecular basis of disease
|January 21, 2025
概括
癌症相关的缓冲症 (CAC) 涉及体重减轻和虚弱. 升高的Lipocalin 2 (LCN2) 可能会抑制食欲,这表明LCN2是缓冲症的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 代谢障碍 代谢障碍 代谢障碍
- 分子生物学分子生物学
背景情况:
- 癌症相关的 (CAC) 是一种复杂的疾病,癌症患者的特征是显著的体重减轻,肌肉消耗和营养缺陷.
- 厌食症是CAC的常见症状,由瘤相关的因素,如炎症性细胞因子和荷尔蒙干扰,导致食物摄入量减少和恶化疾病进展.
- 目前对CAC的治疗选择有限,原因是复杂的病原和难以确定有效的治疗点.
研究的目的:
- 探索Lipocalin 2 (LCN2) 在癌症相关的缓冲症和厌食症的发展和进展中的作用.
- 调查LCN2作为一种新的治疗点在癌症患者中缓解缓解症的潜力.
- 审查现有研究,将LCN2水平与食欲抑制联系起来,以及其对癌症的影响.
主要方法:
- 检查癌症患者中的Lipocalin 2 (LCN2) 水平的体外,体内和临床研究的综述.
- 分析LCN2的作用机制,包括它与黑色皮质素-4受体的结合以及对食欲调节的影响.
- 探索LCN2升高与与癌症相关的缓冲症和厌食症的症状之间的关联.
主要成果:
- 在癌症患者中观察到升高的Lipocalin 2 (LCN2) 水平.
- 通过与黑色皮质素-4受体相互作用,LCN2似乎抑制了食欲,从而导致癌症中的厌食症.
- 现有研究表明,LCN2水平与食欲下降之间存在相关性,突出显示了它在缓解症病原发生过程中的潜在作用.
结论:
- 利波卡林2 (LCN2) 是癌症相关的缓冲症和厌食症的治疗标的有希望的候选者.
- 需要进一步进行精心设计的临床试验,以验证LCN2作为缓冲症治疗的有效性和安全性.
- 了解LCN2在缓冲症中的作用为改善癌症患者的营养状况和生活质量提供了新的途径.
相关概念视频
01:31The Intrinsic Apoptotic Pathway
6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
02:55The Nucleolus
8.7K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.7K